Re-engineering a mobile-CRISPR/Cas9 system for antimicrobial resistance gene curing and immunization in<i>Escherichia coli</i>

Abstract

The IS26-based CRISPR/Cas9 system can be used to efficiently sensitize clinical Escherichia coli isolates to antibiotics in vitro. The single-guide RNAs targeted resistance genes or replication genes of specific incompatible plasmids that harboured resistance genes, providing a novel means to naturally select bacteria that cannot uptake and disseminate such genes.